Edgewise Therapeutics Inc

EWTX

Equity

ISIN null / Valor 110444153

NASDAQ (2025-11-21)

USD 22.67+1.89%

Edgewise Therapeutics Inc
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Edgewise Therapeutics Inc. is a biopharmaceutical company specializing in the development of innovative treatments for muscle diseases, including muscular dystrophies and severe cardiac conditions. The company leverages its expertise in muscle biology and small molecule drug discovery to create a proprietary platform focused on muscle-targeted therapies. Edgewise Therapeutics aims to address unmet medical needs by developing novel therapeutics that can significantly impact the lives of patients and families affected by these serious conditions.

Summarized from source with an LLMView SourceSector: Healthcare

Increased Cash Reserves

Edgewise Therapeutics Inc raised approximately $188 million from the April 2025 public offering, bringing the pro-forma cash balance to over $624 million.

Research and Development Investments

R&D expenses for the first quarter of 2025 were $36.8 million, a slight increase from $36.4 million in the preceding quarter, primarily due to higher personnel costs and expanded clinical development activities.

Summarized from source with an LLMView Source

Key figures

-29.1%1Y

127%3Y

%5Y

Performance

70.8%1Y

75.5%3Y

79.0%5Y

Volatility